MATTERS Study - Mistral Percutaneous Tricuspid Valve Repair FIM Study

Tricuspid Valve Regurgitation Clinical Trial

Official title:

MATTERS Study - Mistral Percutaneous Tricuspid Valve Repair FIM Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04071652
• Other study ID #: CL-475
• Status: Completed
• Phase: N/A
• Start date: August 8, 2017
• Est. completion date: February 28, 2023

Study information

• Verified date: October 2023
• Source: Mitralix
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).

The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.

Description:

The study is designed to clinically demonstrate device acute safety and technical performance (Primary Endpoints) along with longer FU device safety and effectiveness evaluation (Secondary Endpoint).

The main objectives of the study are :

• Evaluate the Acute safety of the implanted Mistral device post procedure and at 30 day follow up period.

• Evaluate the long term Safety of the device.

• Demonstrate effectiveness of the Mistral device in reducing TR.

Primary endpoints:

• Safety: Acute safety. Rate of device related SAE including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event. At discharge and 30 days.

• Performance: Mistral Implantation rate of technical success (defined as successful device implantation with grasped chords from at least two leaflets.).

Secondary endpoints:

• Safety: Safety at 3, 6 and 12 months. Rate of device related SAEs at 3, 6 and 12 months.

• Effectiveness: TR reduction post-procedure, at discharge and 30 days, 3 and 6 months. Improved NYHA class, 6MWTdistance and KCCQ (quality of life) at 30 days, 3 and 6 months.

Relevant only for patients 11-20:

• Safety: Safety at 3, 6, 12 and 24 months. Rate of device related SAEs at 3, 6, 12 and 24 months.

• Effectiveness: TR reduction post-procedure, at discharge and 30 days, 3, 6, 12 and 24 months. Improved NYHA class, 6MWT distance and KCCQ (quality of Life) at 30 days, 3, 6, 12 and 24 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: February 28, 2023
• Est. primary completion date: October 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject has given signed study Informed Consent for participation prior to procedure.

• Subject is = 18 years of age or legal age in host country

• Subject is willing and able to comply with all required follow-up evaluations

• Genders eligible for the study: Both genders

• Subject has TR of grade 3+ or more

• Subject has left ventricular ejection fraction (LVEF) >20 %

• Subject is of functional class 2 or more (NYHA)

• The subject is high risk to undergo TV surgery as assessed and consented by a cardiac surgeon and an interventional cardiologist at the site (center heart team), and according to ESC/EACTS guidelines on the management of valvular heart disease.

• Patients with Jugular and/or Femoral veins enabling catheterization with 12Fr catheters

• Life expectancy = 1 year

Exclusion Criteria:

• Tricuspid Stenosis >mild

• Tricuspid Subvalvular calcification or calcification of the chordae.

• Subject has a history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months.

• Subject has a history of a myocardial infarction (MI) in the past 3 months

• Subject has had a percutaneous interventional or other invasive cardiac or peripheral procedure = 7 days of the index procedure

• Subject has a history of, or has active endocarditis

• Subject has echocardiographic evidence of intra-cardiac mass, thrombus, vegetation or soft-mobile deposits

• Subject is in acute pulmonary edema.

• Subject has hemodynamic instability requiring inotropic or mechanical support.

• Subject has a known hypersensitivity or contraindication to anticoagulant or antiplatelet medication

• Subject has renal insufficiency as evidenced by a serum Creatinine > 3.0mg/dL.

• Subject has ongoing infection or sepsis

• Subject has blood dyscrasias (leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy)

• Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within the past 3 months prior to the index procedure

• Subject requires emergency surgery for any reason

• Subject has a known allergy to Nitinol alloys, 316L\304 stainless steel.

• Pregnant or lactating women.

• Patients being dependent upon the sponsor or upon the investigator or upon the investigational site.

• Subject has a known contrast media allergy

• Presence of high degree atrio-ventricular block (2nd or 3rd degree A-V block), or the presence of tri-fascicular block

• According to investigator on site the patient is suffering from a severe end stage disease (e.g. malignancy, severe pulmonary disease, liver disease, renal failure) and has a life expectancy of less than 1 year.

• Contraindication for treatment with dual antiplatelet therapy for at least 3 months

• Contraindication for TEE including trans-gastric views.

Related Conditions & MeSH terms

• Tricuspid Valve Insufficiency
• Tricuspid Valve Regurgitation

Intervention

Device:
• Mistral implantation
Mistral implant is implanted in the Tricuspid valve

Locations

Country	Name	City	State
Israel	Haddassah	Jerusalem	Kiryat Hadassah
Israel	The Chain Sheba Medical Center at Tel HaShomer	Ramat Gan
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Mitralix

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: Acute safety. Rate of device related SAE	including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event	Until hospital discharge - up to 5 days post procedure day
Primary	Safety: Acute safety. Rate of device related SAE	including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event	At 30 days post procedure
Primary	Performance: Mistral Implantation rate of technical success	defined as successful device implantation with grasped chords from at least two leaflets	Procedure
Secondary	Safety: Rate of device related SAE		at 3 months post procedure
Secondary	Safety: Rate of device related SAE		at 6 months post procedure
Secondary	Safety: Rate of device related SAE		at 12 months post procedure
Secondary	Safety: Rate of device related SAE	Relevant only for patients 11-20	at 24 months post procedure
Secondary	Effectiveness: TR Grade reduction		post procedure (1 hour after implant device has been implanted)
Secondary	Effectiveness: TR Grade reduction		Until hospital discharge - up to 5 days post procedure day
Secondary	Effectiveness: TR Grade reduction		at 30 days post procedure
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)		at 30 days post procedure
Secondary	Effectiveness: 6MWT distance		at 30 days post procedure
Secondary	Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire)		at 30 days post procedure
Secondary	Effectiveness: TR Grade reduction		at 3 months post procedure
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)		at 3 months post procedure
Secondary	Effectiveness: 6MWT distance		at 3 months post procedure
Secondary	Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire)		at 3 months post procedure
Secondary	Effectiveness: TR Grade reduction		at 6 months post procedure
Secondary	Effectiveness: TR Grade reduction	Relevant only for patients 11-20	at 12 months post procedure
Secondary	Effectiveness: TR Grade reduction	Relevant only for patients 11-20	at 24 months post procedure
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)		at 6 months post procedure
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)	Relevant only for patients 11-20	at 12 months post procedure
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)	Relevant only for patients 11-20	at 24 months post procedure
Secondary	Effectiveness: 6MWT distance		at 6 months post procedure
Secondary	Effectiveness: 6MWT distance	Relevant only for patients 11-20	at 12 months post procedure
Secondary	Effectiveness: 6MWT distance	Relevant only for patients 11-20	at 24 months post procedure
Secondary	Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire)		at 6 months post procedure
Secondary	Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire)	Relevant only for patients 11-20	at 12 months post procedure
Secondary	Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire)	Relevant only for patients 11-20	at 24 months post procedure